Portage Biotech 株価情報 (NASDAQ: PRTG)

最新ニュース Portage Biotech (NASDAQ:PRTG) 株価情報

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech Inc

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and raises the price target from $303 to $304.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Chubb, Raises Price Target to $304

General

NXPL

NextPlat  Receives Nasdaq Letter Regarding Minimum Bid Requirements

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $139 to $142.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $142

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $29.10 million which beat the analyst consensus estimate of $28.21 million by 3.17 percent. This is a 33.36 percent increase over sales of $21.82 million the same period last year.

Earnings

Earnings Beats

EVLV

Evolv Technologies Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $29.10M Beat $28.21M Estimate

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $27.36 million which beat the analyst consensus estimate of $26.32 million by 3.95 percent. This is a 35.51 percent increase over sales of $20.19 million the same period last year.

Evolv Technologies Q3 2024 Adj. EPS $(0.04) Beats $(0.06) Estimate, Sales $27.36M Beat $26.32M Estimate

Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBNK#NASDAQ">CBNK</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.72 by 22.22 percent. This is a 72.55 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $58.60 million which beat the analyst consensus estimate of $57.43 million by 2.03 percent. This is a 42.99 percent increase over sales of $40.98 million the same period last year.

CBNK

Capital Bancorp Q1 Adj. EPS $0.88 Beats $0.72 Estimate, Sales $58.60M Beat $57.43M Estimate

UBS analyst Myles Walton maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Neutral and raises the price target from $222 to $226.

UBS Maintains Neutral on L3Harris Technologies, Raises Price Target to $226

SunCar Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) reported $441.90 million in sales this quarter. This is a 21.49 percent increase over sales of $363.75 million the same period last year.

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Group FY 2024 Revenue $441.90M Up From $363.75M YoY

UBS analyst Brian Meredith maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Buy and raises the price target from $73 to $78.

UBS Maintains Buy on WR Berkley, Raises Price Target to $78

UBS analyst Jay Sole maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $56 to $59.

ONON

UBS Maintains Buy on On Holding, Raises Price Target to $59

UBS analyst Gavin Parsons maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Sell and raises the price target from $62 to $63.

UBS Maintains Sell on Textron, Raises Price Target to $63

SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) affirms FY2025 Adj EPS guidance from $2.90-$3.00 to $2.90-$3.00 vs $2.97 analyst estimate..

Guidance

SJW Gr Affirms FY2025 Adj EPS Guidance of $2.90-$3.00 vs $2.97 Est

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 Adj EPS of $0.41-$0.64 vs $0.52 analyst estimate. sees sales of $610.000 million-$680.000 million vs $643.53 million analyst estimate.

Teradyne Sees Q2 Adj EPS $0.41-$0.64 vs $0.52 Est; Sees Sales $610.000M-$680.000M vs $643.53M Est

SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.36 by 38.89 percent. This is a 38.89 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $167.60 million which beat the analyst consensus estimate of $159.03 million by 5.39 percent. This is a 12.19 percent increase over sales of $149.38 million the same period last year.

SJW Gr Q1 Adj. EPS $0.50 Beats $0.36 Estimate, Sales $167.60M Beat $159.03M Estimate

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.62 by 20.97 percent. This is a 47.06 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $685.68 million which beat the analyst consensus estimate of $680.51 million by 0.76 percent. This is a 14.31 percent increase over sales of $599.82 million the same period last year.

Teradyne Q1 Adj. EPS $0.75 Beats $0.62 Estimate, Sales $685.68M Beat $680.51M Estimate

Transocean, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/g45052677/transocean-ltd-reports-first-quarter-2025-results"> from the report. </a>
The Details: Transocean reported first-quarter losses of 10 cents per share, which missed the analyst consensus estimate for losses of nine cents. Quarterly revenue clocked in at $906 million, beating the consensus estimate of $885.7 million.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Transocean reported: 
<ul>
<li>Contract drilling revenues for the quarter decreased sequentially by $46 million to $906 million. </li>
<li>Operating and maintenance expense was $618 million, compared with $579 million in the prior quarter. The sequential increase was the result of an unfavorable legal outcome in the first quarter, a favorable legal settlement in the fourth quarter and increased costs related to a rig in shipyard, partially offset by lower in-service maintenance costs across the fleet.</li>
<li>General and administrative expense was $50 million, down from $56 million in the fourth quarter, due primarily to decreased legal and professional fees.</li>
</ul>
&#8220;The Transocean team delivered a solid quarter, with an adjusted EBITDA of $244 million on revenues of $906 million,&#8221; said CEO Jeremy Thigpen. &#8220;We also improved our balance sheet with the repayment of $210 million in outstanding debt.&#8221;
&#8220;While uncertain macroeconomic conditions have resulted in near-term market volatility, including commodity prices, Transocean is very well-positioned to navigate this evolving landscape.&nbsp;In addition to continuing to deliver strong operating performance across our highly contracted fleet, we remain engaged in constructive conversations with our customers on opportunities several years in the future,&#8221; Thigpen added. 
RIG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Transocean stock was up 1.30% after-hours at $2.31 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats

Management

ARMN

Aris Mining's Richard Orazietti To Step Down As CFO Following The Completion Of The Company's Q1 2025 Reporting

CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) reported quarterly earnings of $2.56 per share. This is a 115.13 percent increase over earnings of $1.19 per share from the same period last year. The company reported $142.87 million in sales this quarter. This is a 11.91 percent increase over sales of $127.67 million the same period last year.

CVR Partners Q1 EPS $2.56 Up From $1.19 YoY, Sales $142.87M Up From $127.67M YoY

CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.89) by 34.83 percent. This is a 1550 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.31 billion by 25.82 percent. This is a 11.65 percent decrease over sales of $1.86 billion the same period last year.

CVR Energy Q1 Adj. EPS $(0.58) Beats $(0.89) Estimate, Sales $1.65B Beat $1.31B Estimate

Biotech

NGNE

Neurogene To Give Oral Presentation On Monitoring And Treatment To Reverse Rare Complication of High-Dose Gene Therapy At the ASGCT Annual Meeting

Press Releases

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Health Care

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

LXRX

PRSO

PRTG

RNAZ

ABVC BioPharma

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Comments

Portage Biotech

ニュース

最新ニュース Portage Biotech (NASDAQ:PRTG) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル